Selected research
Industry Research
Atazanavir Industry Research Report 2026
Market perspective
The global Atazanavir market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Atazanavir is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Atazanavir is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Atazanavir is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Atazanavir include TEVA, Mylan, Emcure, Cipla, Bristol-Myers Squibb and Aurobindo Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Atazanavir market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Atazanavir Market by Company
TEVA
Mylan
Emcure
Cipla
Bristol-Myers Squibb
Aurobindo Pharma
Atazanavir Segment by Type
50 mg Oral Powder
300 mg Capsule
200 mg Capsule
150 mg Capsule
Atazanavir Segment by Application
Adults
Children 3 months of age and older
Atazanavir Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atazanavir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Atazanavir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atazanavir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Atazanavir manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Atazanavir by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Atazanavir in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50 mg Oral Powder
- 300 mg Capsule
- 200 mg Capsule
- 150 mg Capsule
Applications
- Adults
- Children 3 months of age and older
Companies covered
- TEVA
- Mylan
- Emcure
- Cipla
- Bristol-Myers Squibb
- Aurobindo Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Atazanavir Market Size (2021-2032)
- 2.2.2 Global Atazanavir Sales (2021-2032)
- 2.2.3 Global Atazanavir Market Average Price (2021-2032)
- 2.3 Atazanavir by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 50 mg Oral Powder
- 2.3.3 300 mg Capsule
- 2.3.4 200 mg Capsule
- 2.3.5 150 mg Capsule
- 2.4 Atazanavir by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Children 3 months of age and older
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Atazanavir Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Atazanavir Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Atazanavir Revenue of Manufacturers (2021-2026)
- 3.4 Global Atazanavir Average Price by Manufacturers (2021-2026)
- 3.5 Global Atazanavir Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Atazanavir, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Atazanavir, Product Type & Application
- 3.8 Global Manufacturers of Atazanavir, Established Date
- 3.9 Global Atazanavir Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 TEVA
- 4.1.1 TEVA Company Information
- 4.1.2 TEVA Business Overview
- 4.1.3 TEVA Atazanavir Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 TEVA Atazanavir Product Portfolio
- 4.1.5 TEVA Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Atazanavir Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Atazanavir Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Emcure
- 4.3.1 Emcure Company Information
- 4.3.2 Emcure Business Overview
- 4.3.3 Emcure Atazanavir Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Emcure Atazanavir Product Portfolio
- 4.3.5 Emcure Recent Developments
- 4.4 Cipla
- 4.4.1 Cipla Company Information
- 4.4.2 Cipla Business Overview
- 4.4.3 Cipla Atazanavir Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Cipla Atazanavir Product Portfolio
- 4.4.5 Cipla Recent Developments
- 4.5 Bristol-Myers Squibb
- 4.5.1 Bristol-Myers Squibb Company Information
- 4.5.2 Bristol-Myers Squibb Business Overview
- 4.5.3 Bristol-Myers Squibb Atazanavir Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bristol-Myers Squibb Atazanavir Product Portfolio
- 4.5.5 Bristol-Myers Squibb Recent Developments
- 4.6 Aurobindo Pharma
- 4.6.1 Aurobindo Pharma Company Information
- 4.6.2 Aurobindo Pharma Business Overview
- 4.6.3 Aurobindo Pharma Atazanavir Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Aurobindo Pharma Atazanavir Product Portfolio
- 4.6.5 Aurobindo Pharma Recent Developments
5 Global Atazanavir Market Scenario by Region
- 5.1 Global Atazanavir Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Atazanavir Sales by Region: 2021-2032
- 5.2.1 Global Atazanavir Sales by Region: 2021-2026
- 5.2.2 Global Atazanavir Sales by Region: 2027-2032
- 5.3 Global Atazanavir Revenue by Region: 2021-2032
- 5.3.1 Global Atazanavir Revenue by Region: 2021-2026
- 5.3.2 Global Atazanavir Revenue by Region: 2027-2032
- 5.4 North America Atazanavir Market Facts & Figures by Country
- 5.4.1 North America Atazanavir Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Atazanavir Sales by Country (2021-2032)
- 5.4.3 North America Atazanavir Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Atazanavir Market Facts & Figures by Country
- 5.5.1 Europe Atazanavir Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Atazanavir Sales by Country (2021-2032)
- 5.5.3 Europe Atazanavir Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Atazanavir Market Facts & Figures by Country
- 5.6.1 Asia Pacific Atazanavir Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Atazanavir Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Atazanavir Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Atazanavir Market Facts & Figures by Country
- 5.7.1 South America Atazanavir Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Atazanavir Sales by Country (2021-2032)
- 5.7.3 South America Atazanavir Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Atazanavir Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Atazanavir Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Atazanavir Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Atazanavir Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Atazanavir Sales by Type (2021-2032)
- 6.1.1 Global Atazanavir Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Atazanavir Sales Market Share by Type (2021-2032)
- 6.2 Global Atazanavir Revenue by Type (2021-2032)
- 6.2.1 Global Atazanavir Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Atazanavir Revenue Market Share by Type (2021-2032)
- 6.3 Global Atazanavir Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Atazanavir Sales by Application (2021-2032)
- 7.1.1 Global Atazanavir Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Atazanavir Sales Market Share by Application (2021-2032)
- 7.2 Global Atazanavir Revenue by Application (2021-2032)
- 7.2.1 Global Atazanavir Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Atazanavir Revenue Market Share by Application (2021-2032)
- 7.3 Global Atazanavir Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Atazanavir Value Chain Analysis
- 8.1.1 Atazanavir Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Atazanavir Production Mode & Process
- 8.2 Atazanavir Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Atazanavir Distributors
- 8.2.3 Atazanavir Customers
9 Global Atazanavir Analyzing Market Dynamics
- 9.1 Atazanavir Industry Trends
- 9.2 Atazanavir Industry Drivers
- 9.3 Atazanavir Industry Opportunities and Challenges
- 9.4 Atazanavir Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst